Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics (Q33423012)

26 July 2017

Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics (English)

1 reference

26 July 2017

Standl E

1

1 reference

26 July 2017

Schernthaner G

2

1 reference

26 July 2017

Rybka J

3

1 reference

26 July 2017

Hanefeld M

4

1 reference

26 July 2017

Raptis SA

5

1 reference

26 July 2017

Naditch L

6

1 reference

26 July 2017

1 March 2001

1 reference

Diabetes Research and Clinical Practice

26 July 2017

1 reference

26 July 2017

51

1 reference

26 July 2017

205-213

1 reference

26 July 2017

3

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Metformin-associated lactic acidosis in Sweden 1977-1991

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Acarbose: its role in the treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

Drug therapy of postprandial hyperglycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900231-X

7 January 2021

10.1016/S0168-8227(00)00231-X

Identifiers

DOI

1 reference

26 July 2017

1 reference